Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Cisplatin and Bevacizumab in Triple-Negative Breast Cancer
NCT00580333Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2007
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in triple-negative breast cancer (TNBC), sponsored by Massachusetts General Hospital. Started Sep 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00580333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00580333.